1. Home
  2. ELS vs HALO Comparison

ELS vs HALO Comparison

Compare ELS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELS

Equity Lifestyle Properties Inc.

HOLD

Current Price

$61.07

Market Cap

12.8B

Sector

Real Estate

ML Signal

HOLD

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$107.39

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELS
HALO
Founded
1992
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8B
12.0B
IPO Year
1994
2001

Fundamental Metrics

Financial Performance
Metric
ELS
HALO
Price
$61.07
$107.39
Analyst Decision
Buy
Buy
Analyst Count
10
11
Target Price
$70.25
$78.64
AVG Volume (30 Days)
1.1M
1.7M
Earning Date
04-21-2026
05-05-2026
Dividend Yield
3.49%
N/A
EPS Growth
2.55
N/A
EPS
0.56
3.11
Revenue
$1,531,382,000.00
$151,862,000.00
Revenue This Year
$3.97
$28.24
Revenue Next Year
$4.69
$12.56
P/E Ratio
$110.41
$34.83
Revenue Growth
0.34
N/A
52 Week Low
$58.72
$61.23
52 Week High
$69.00
$111.15

Technical Indicators

Market Signals
Indicator
ELS
HALO
Relative Strength Index (RSI) 29.07 62.16
Support Level $60.25 $103.47
Resistance Level $63.83 N/A
Average True Range (ATR) 0.85 2.52
MACD -0.36 -0.90
Stochastic Oscillator 6.57 42.45

Price Performance

Historical Comparison
ELS
HALO

About ELS Equity Lifestyle Properties Inc.

Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company has a portfolio of 453 properties across the US with a higher concentration in the Sun Belt; 38% of its properties are in Florida, 11% in Arizona, and 10% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: